Alector
Alector’s mission is to develop therapies that empower the immune system to cure neuro-degeneration and cancer.
AM–Pharma
AM–Pharma is
developing disease modifying Alkaline Phosphatase therapeutics.
ApoGen Biotechnologies
ApoGen Biotechnologies is developing a new class of therapies that target key drivers of ongoing DNA mutation and tumor evolution.
Aquinnah Pharmaceuticals
Aquinnah Pharmaceuticals is developing small molecule therapeutics targeting persistent stress granules for the treatment of neurodegenerative disease.
Artios Pharma
Artios
Pharma is developing cancer treatments that target DNA Damage
Response pathways to selectively kill cancer cells.
Caraway Therapeutics
Caraway Therapeutics is working to develop novel treatments for neurodegenerative disease through modulation of mitophagy and autophagy.
Carisma Therapeutics
Carisma Therapeutics is developing Chimeric Antigen Receptor-expressing macrophages to target and destroy solid tumors.
Disarm Therapeutics
Disarm Therapeutics is creating disease-modifying therapeutics for patients with neurological diseases by directly treating axonal degeneration.
eFFECTOR Therapeutics
eFFECTOR Therapeutics is developing selective translation regulators as a new class of small molecule therapeutics for cancer and other serious diseases.
E-Scape Bio
E-Scape Bio is developing therapeutics against genetic targets for neurodegenerative disease.
Jnana Therapeutics
Jnana Therapeutics is building the first drug discovery platform dedicated to the solute carrier family of transporters.
Lodo Therapeutics
Lodo Therapeutics is a drug discovery and development company focused on the creation of novel therapeutics derived from nature that will impact patients around the world.
Magnolia Neurosciences
Magnolia Neurosciences is developing potent and highly selective neuroprotective therapies.
Morphic Therapeutic
Morphic Therapeutic is working to develop the first orally administered integrin therapeutics for patients with immunological, fibrotic, neoplastic, and vascular diseases.
PACT Pharma
PACT is developing personalized adoptive cell therapies based on neoantigen-targeted T cells against cancer.
Palleon Pharmaceuticals
Palleon Pharmaceuticals is targeting glycan-sensing checkpoints to unleash both the innate and adaptive immune responses to cancer.
Petra Pharma
Petra Pharma is dedicated to discovering and developing novel therapies that modulate phosphoinositide signaling pathways for the treatment of cancer and other serious diseases.
Prevail
Prevail is developing disease-modifying gene therapies for patients with Parkinson’s disease and other neurodegenerative disorders.
Quentis Therapeutics
Quentis is
pioneering first in class immunotherapies that modulate endoplasmic
reticulum stress response pathways in the tumor
microenvironment.
Ribometrix
Ribometrix is a platform therapeutics company discovering small molecule drugs that target functional 3D RNA structures to treat human disease.
Ribon Therapeutics
Ribon is dedicated to the discovery and development of first-in-class small molecule inhibitors to block cancer cells' fundamental ability to survive under stress.
Rodeo Therapeutics
Rodeo Therapeutics is a preclinical-stage biotech company focused on first in class small molecule modulators of prostaglandin biology for enhancing tissue repair and regeneration.
Tizona
Tizona Therapeutics, Inc. is an immunology company harnessing the power of the immune system to develop treatments for cancer.